<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191231045967N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-02-11</date_registration>
      <primary_sponsor>Yazd University of Medical Sciences</primary_sponsor>
      <public_title>Determining the effect of vitamin D3 and positive group counseling with lifestyle changes in premenstrual women of reproductive age</public_title>
      <acronym></acronym>
      <scientific_title>Survey  the effect of vitamin D3 tablet intake, positivism group consulting with changing in life style in the treatment of premenstrual syndrome in women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>84</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/45331</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple random sampling
In this way, we first obtain the list of all members, then assign a score to each of them, and select the required number using the random number table.</study_design>
      <phase>3</phase>
      <hc_freetext>Women's premenstrual syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group consuming vitamin D3, with a criterion and after determining 25 hydroxyvitamin D level, subjects with serum level less than 30 ng / ml will be included in the study. Each person is given 6 capsules of vitamin D 50000, D3 to take 1 dose per week for 6 weeks. After 6 weeks of administration and determination of 25-جhydroxytryptamine serum level, the physician is instructed to take one vitamin D within 4 weeks. 50,000 units manufactured by the pharmaceutical company are disposed of and re-measured at the end of the intervention. The premenstrual syndrome form is completed before the study, at 6 weeks and 10 weeks after the intervention. Satisfaction with intervention methods is assessed in weeks 6 and 10. Intervention 2: Intervention group: In the intervention group, 6 group sessions will be held  online because of covid 19 pandemic once a week for 90 minutes in a positive-group group. After selecting the women for the meetings, we select the days of the two groups' meetings as suggested by the women on two different days of the week so that the two groups receiving the consultation do not interact with each other. , Second session, gratitude meeting, third session, constructive active response, fourth session, counting blessings, fifth session, sense of taste, sixth session, preservation of therapeutic effects. Pre-menstrual syndrome form before study, 6 weeks intervention and Week 10 was completed after the intervention. Satisfaction with intervention method is assessed in weeks 6 and 10. Intervention 3: Control group: Lifestyle group sessions on appropriate physical activity, weight and fitness control, healthy eating, menstrual mental health, tobacco harm and familiarity with early detection methods of common female cancer (breast and cervical cancer) and during 6 sssions for 2 groups are held in two days, 6 sessions online because of covid 19 pandemic. The premenstrual syndrome form is completed before the study, at 6 weeks and 10 weeks after the intervention. Satisfaction with intervention method is assessed in weeks 6 and 10.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is I haven't decided yet to finish the study.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Tahmineh Faraj Khoda</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Fars, Arsanjan city, Imam Khomeini town</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7376187999</zip>
        <telephone>009843527244</telephone>
        <email>maryam.mahmoodi8874@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Tahmineh Faraj Khoda</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Fars, Arsanjan city, Imam Khomeini town</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7376187999</zip>
        <telephone>009843527244</telephone>
        <email>maryam.mahmoodi8874@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Being a resident of Rafsanjan city
No history of treatment or depression or anxiety disorder
No history of treatment or eating disorder
No history of treatment or anemia disorder
No history of treatment or thyroid disorder
No history of treatment or presence of diabetes
Not taking birth control pills for medical reasons
Not taking any herbal medicine or medicine that affects premenstrual syndrome
Lack of treatment with psychiatric drugs and other non-pharmacological methods
Lack of treatment with other non-medicinal methods
Having two consecutive menstrual cycles a year with symptoms of premenstrual syndrome with at least five symptoms, one of which are mood disorders, which begin in the second half of the menstrual cycle and improve after menstruation, according to the self-report.
Having at least a 30% increase in symptom severity within 5 days before menstruation based on the PMS
Willingness to continue collaborating on tasks for 6 weeks
Failure to participate in another related study until the expiration of the current study</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Severe form of premenstrual syndrome with a score of 35 and more from the premenstrual syndrome calendar</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N94.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Premenstrual tension syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Behavior</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group consuming vitamin D3, with a criterion and after determining 25 hydroxyvitamin D level, subjects with serum level less than 30 ng / ml will be included in the study. Each person is given 6 capsules of vitamin D 50000, D3 to take 1 dose per week for 6 weeks. After 6 weeks of administration and determination of 25-جhydroxytryptamine serum level, the physician is instructed to take one vitamin D within 4 weeks. 50,000 units manufactured by the pharmaceutical company are disposed of and re-measured at the end of the intervention. The premenstrual syndrome form is completed before the study, at 6 weeks and 10 weeks after the intervention. Satisfaction with intervention methods is assessed in weeks 6 and 10.</i_keyword>
      <i_keyword>Intervention group: In the intervention group, 6 group sessions will be held  online because of covid 19 pandemic once a week for 90 minutes in a positive-group group. After selecting the women for the meetings, we select the days of the two groups' meetings as suggested by the women on two different days of the week so that the two groups receiving the consultation do not interact with each other. , Second session, gratitude meeting, third session, constructive active response, fourth session, counting blessings, fifth session, sense of taste, sixth session, preservation of therapeutic effects. Pre-menstrual syndrome form before study, 6 weeks intervention and Week 10 was completed after the intervention. Satisfaction with intervention method is assessed in weeks 6 and 10.</i_keyword>
      <i_keyword>Control group: Lifestyle group sessions on appropriate physical activity, weight and fitness control, healthy eating, menstrual mental health, tobacco harm and familiarity with early detection methods of common female cancer (breast and cervical cancer) and during 6 sssions for 2 groups are held in two days, 6 sessions online because of covid 19 pandemic. The premenstrual syndrome form is completed before the study, at 6 weeks and 10 weeks after the intervention. Satisfaction with intervention method is assessed in weeks 6 and 10.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>1-Mean premenstrual syndrome scores, 2- Satisfaction with intervention methods. Timepoint: 1-ّFor  premenstrual syndrome before the intervention, complete the sixth week of the intervention and finish the tenth week.2- At the end of 6 and 10 weeks. Method of measurement: 1-Premenstrual Syndrome Screening Tool , 2-Satisfaction tool.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yazd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-12-31</approval_date>
        <contact_name>Ethics Committee of Shahid Sadoughi University of Medical Sciences</contact_name>
        <contact_address>Fars, Arsanjan city, Imam Khomeini town, Modarres Alley 4 yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
